Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Operable breast cancer without axillary node involvement: current therapeutic concepts].

M J Piccart

    Revue Medicale De Bruxelles
    |December 1, 1989
    PubMed
    Summary

    For node-negative breast cancer patients, adjuvant therapy after surgery offers a survival benefit. Research is exploring new prognostic factors to identify high-risk individuals who will benefit most from treatment.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Erratum to "Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust": [Annals of Oncology 32 (2021) 1077-1082].

    Annals of oncology : official journal of the European Society for Medical Oncology·2022
    Same author

    Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust.

    Annals of oncology : official journal of the European Society for Medical Oncology·2021
    Same author

    Reply to the letter to the editor 'The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice' by Hartmann and the letter 'Comment on ESMO Magnitude of Clinical Benefit Scale' by Muhonen et al.

    Annals of oncology : official journal of the European Society for Medical Oncology·2020
    Same author

    Reply to the letter to the editor 'Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies'.

    Annals of oncology : official journal of the European Society for Medical Oncology·2017
    Same author

    Reply to the letter to the editor 'Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?' by Del Paggio.

    Annals of oncology : official journal of the European Society for Medical Oncology·2017
    Same author

    ESMO-Magnitude of Clinical Benefit Scale version 1.1.

    Annals of oncology : official journal of the European Society for Medical Oncology·2017

    Area of Science:

    • Oncology
    • Clinical Trials
    • Breast Cancer Research

    Background:

    • Most node-negative breast cancer patients remain disease-free at 10 years.
    • However, 25-30% experience recurrence and mortality.
    • Current treatment strategies are evolving.

    Purpose of the Study:

    • To review recent clinical trials on adjuvant therapy for node-negative breast cancer.
    • To discuss novel prognostic factors for risk stratification.
    • To explore treatment benefits and toxicity.

    Main Methods:

    • Review of recently published randomized clinical trials.
    • Literature review on prognostic factors.
    • Discussion of treatment toxicity and future research.

    Related Experiment Videos

    Main Results:

    • Adjuvant chemo- or hormonal therapy shows a small but significant disease-free survival advantage at 4 years.
    • Identification of potential new prognostic factors is crucial for patient selection.
    • Treatment toxicity is a key consideration.

    Conclusions:

    • Adjuvant therapy offers a survival benefit for select node-negative breast cancer patients.
    • Prognostic factors are essential for tailoring treatment and maximizing benefits.
    • Further research is needed to optimize adjuvant therapy strategies.